Brett King, Natasha Mesinkovska, Paradi Mirmirani, Suzanne Bruce, Steve Kempers, Emma Guttman-Yassky, Janet L Roberts, Amy McMichael, Maria Colavincenzo, Colleen Hamilton, Virginia Braman, James V Cassella
BACKGROUND: Janus kinase (JAK) activation is suggested to have a pathological role in alopecia areata (AA). CTP-543, a deuterated compound that selectively inhibits JAK1 and JAK2, is being developed as an oral treatment for AA. OBJECTIVE: To assess the safety and efficacy of a 24-week regimen of CTP-543 in patients with chronic, moderate-to-severe AA. METHODS: In this phase 2, randomized, double-blind, placebo-controlled, sequential-design trial, patients were randomized to receive CTP-543 (4 mg, 8 mg, or 12 mg) or placebo every 12 hours for 24 weeks...
August 2022: Journal of the American Academy of Dermatology